Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

2 years ago

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing…

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024

2 years ago

NAARDEN, the Netherlands and MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or…

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

2 years ago

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low…

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

2 years ago

KR-HT5 is based on Akoya’s PhenoImager® HT PlatformMARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences,…

Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

2 years ago

MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the…

Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary

2 years ago

LAUPHEIM, Germany and MILFORD, Mass. and STEVENAGE, United Kingdom, May 02, 2024 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading…

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

2 years ago

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP;…

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

2 years ago

May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON,…

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

2 years ago

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in…

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

2 years ago

Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE)…